Formosa pharmaceuticals announces licensing agreement with eyenovia, inc., for the commercialization of app13007 for the treatment of inflammation and pain following ocular surgery

Taipei , aug. 16, 2023 /prnewswire/ -- taiwan-based formosa pharmaceuticals ("formosa", 6838.two) announced today that the company has entered into a licensing agreement with eyenovia, inc. ("eyenovia", nasdaq: eyen), whereby eyenovia obtains exclusive u.s. rights for the commercialization of app13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) for the treatment of inflammation and pain following ocular surgery.  app13007 is currently under review by the u.s. food and drug administration (fda) and has been assigned a prescription drug user fee act (pdufa) date of march 4, 2024.
EYEN Ratings Summary
EYEN Quant Ranking